



Message From the Editor-in-Chief

Hiroaki Shimokawa, MD, PhD

Dear Colleagues,

On behalf of the *Circulation Journal*, I am pleased to report the official 2013 impact factor and the *Circulation Journal* papers (2011–2012) most frequently quoted in 2013, that substantially contributed to the 2012 impact factor of the Journal.

1. The Official 2013 Impact Factor

I am pleased to report that *Circulation Journal* has earned an official 2013 Impact Factor (IF) of **3.685**. The official ranking also places *Circulation Journal* **36th** among the **125** journals in the Cardiac & Cardiovascular Systems category in 2013 JCR Science Edition (33th among the 124 journals in 2012).

2. The Most Frequently Quoted CJ Papers (2011–2012) in 2013

The following papers, published in 2011–2012, were among the top **31** most frequently quoted papers in 2013, thereby substantially contributing to the 2013 Impact Factor of the Journal (number in the parenthesis denoted the number of quotation in 2011–2012).

1. (29) Manabe I. Chronic inflammation links cardiovascular, metabolic and renal diseases. *Circ J* 2011; **75**: 2739–2748.
2. (25) Curcio A, Torella D, Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: Approach to therapy. *Circ J* 2011; **75**: 1287–1296.
3. (23) Kaseno K, Naito S, Nakamura K, Sakamoto T, Sasaki T, Tsukada N, et al. Efficacy and safety of periprocudural dabigatran in patients undergoing catheter ablation of atrial fibrillation. *Circ J* 2012; **76**: 2337–2342.
- (23) Berne P, Brugada J. Brugada syndrome 2012. *Circ J* 2012; **76**: 1563–1571.
5. (20) Antzelevitch C. Genetic, molecular and cellular mechanisms underlying the J wave syndromes. *Circ J* 2012; **76**: 1054–1065.
6. (19) Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al; on behalf of the J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: The J-ROCKET AF Study. *Circ J* 2012; **76**: 2104–2111.
7. (18) Fukumoto Y, Shimokawa H. Recent progress in the management of pulmonary hypertension. *Circ J* 2011; **75**: 1801–1810.
- (18) Auricchio A, Prinzen FW. Non-responders to cardiac resynchronization therapy: The magnitude of the problem and the issues. *Circ J* 2011; **75**: 521–527.
9. (16) Saito I. Epidemiological evidence of type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease in Japan. *Circ J* 2012; **76**: 1066–1073.
10. (15) Kumagai K. Catheter ablation of atrial fibrillation: State of the art. *Circ J* 2011; **75**: 2305–2311.
- (15) Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H; for the J-RHYTHM Registry Investigators. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: A report from the J-RHYTHM Registry. *Circ J* 2011; **75**: 1328–1333.
12. (14) Choi SH, Jung SY, Kwon SM, Baek SH. Perspectives on stem cell therapy for cardiac regeneration: Advances and challenges. *Circ J* 2012; **76**: 1307–1312.
- (14) Minamino T. Cardioprotection from ischemia/reperfusion injury: Basic and translational research. *Circ J* 2012; **76**: 1074–1082.
- (14) Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation: The ARISTOTLE-J study. *Circ J* 2011; **75**: 1852–1859.
- (14) New SEP, Aikawa E. Cardiovascular calcification: An inflammatory disease. *Circ J* 2011; **75**: 1305–1313.
16. (13) Hayashi Y, Iwami T, Kitamura T, Nishiuchi T, Kajino K, Sakai T, et al. Impact of early intravenous epinephrine administration on outcomes following out-of-hospital cardiac arrest. *Circ J* 2012; **76**: 1639–1645.

17. (12) Saku K, Zhang B, Noda K; on behalf of the PATROL Trial Investigators. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): The PATROL trial. *Circ J* 2011; **75**: 1493–1505.
- (12) Hori M, Connolly SJ, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L; the RE-LY Investigators. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation: Sub-analysis in Japanese population in RE-LY trial. *Circ J* 2011; **75**: 800–805.
19. (11) Ohgashi H, Haraguchi G, Konishi M, Tezuka D, Kamiishi T, Ishihara T, et al. Improved prognosis of Takayasu arteritis over the past decade: Comprehensive analysis of 106 patients. *Circ J* 2012; **76**: 1004–1011.
- (11) Otsuka H, Arimura T, Abe T, Kawai H, Aizawa Y, Kubo T, et al. Prevalence and distribution of sarcomeric gene mutations in Japanese patients with familial hypertrophic cardiomyopathy. *Circ J* 2012; **76**: 453–461.
- (11) Domei T, Yokoi H, Kuramitsu S, Soga Y, Arita T, Ando K, et al. Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention. *Circ J* 2012; **76**: 423–429.
- (11) Mathur S, Walley KR, Wang Y, Indrambarya T, Boyd JH. Extracellular heat shock protein 70 induces cardiomyocyte inflammation and contractile dysfunction via TLR2. *Circ J* 2011; **75**: 2445–2452.
- (11) Ago T, Kuroda J, Kamouchi M, Sadoshima J, Kitazono T. Pathophysiological roles of NADPH oxidase/Nox family proteins in the vascular system: Review and perspective. *Circ J* 2011; **75**: 1791–1800.
- (11) Hatano M, Kinugawa K, Shiga T, Kato N, Endo M, Hisagi M, et al. Less frequent opening of the aortic valve and a continuous flow pump are risk factors for postoperative onset of aortic insufficiency in patients with a left ventricular assist device. *Circ J* 2011; **75**: 1147–1155.
- (11) Kawahara C, Tsutamoto T, Nishiyama K, Yamaji M, Sakai H, Fujii M, et al. Prognostic role of high-sensitivity cardiac troponin T in patients with nonischemic dilated cardiomyopathy. *Circ J* 2011; **75**: 656–661.
- (11) Sawada T, Shinke T, Shite J, Honjo T, Haraguchi Y, Nishio R, et al. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. *Circ J* 2011; **75**: 99–105.
27. (10) Okura H, Takada Y, Yamabe A, Ozaki T, Yamagishi H, Toda I, et al. Prevalence and correlates of physiological valvular regurgitation in healthy subjects: A color Doppler echocardiographic study in the current era. *Circ J* 2011; **75**: 2699–2704.
- (10) Kinugawa K. How to treat stage D heart failure?: When to implant left ventricular assist devices in the era of continuous flow pumps? *Circ J* 2011; **75**: 2038–2045.
- (10) Ogawa S, Koretsune Y, Yasaka M, Aizawa Y, Atarashi H, Inoue H, et al. Antithrombotic therapy in atrial fibrillation: Evaluation and positioning of new oral anticoagulant agents. *Circ J* 2011; **75**: 1539–1547.
- (10) Mogi M, Horiuchi M. Neurovascular coupling in cognitive impairment associated with diabetes mellitus. *Circ J* 2011; **75**: 1042–1048.
- (10) Kubozono T, Miyata M, Ueyama K, Hamasaki S, Kusano K, Kubozono O, et al. Acute and chronic effects of smoking on arterial stiffness. *Circ J* 2011; **75**: 698–702.

The Editorial Team looks forward to receiving manuscripts with high scientific impact from all over the world.

Hiroaki Shimokawa, MD, PhD

Editor-in-Chief
Circulation Journal

(Released online August 4, 2014)